Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

243.09
+20.099.01%
Post-market: 242.18-0.9100-0.37%19:59 EDT
Volume:607.60K
Turnover:144.89M
Market Cap:637.99M
PE:- -
High:246.22
Open:223.71
Low:222.45
Close:223.00
52wk High:341.93
52wk Low:102.35
Shares:2.62M
Float Shares:2.62M
Volume Ratio:1.01
T/O Rate:23.15%
Dividend:0.91
Dividend Rate:0.38%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Health Care up as Humana Rallies

Dow Jones
·
2 hours ago

ETF Daily | MRNX Soars 28%; ASTN Jumps 22%; YINN Advances 7%; Healthcare and China Beta Lead

ETF Tracker
·
3 hours ago

Sector Update: Healthcare

MT Newswires Live
·
4 hours ago

Sector Update: Healthcare

MT Newswires Live
·
6 hours ago

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live
·
6 hours ago

Rubicon Research Reports Procedural Observation After Unannounced US FDA Inspection at Satara Plant

TIPRANKS
·
Yesterday

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

TIPRANKS
·
Yesterday

Movement Alert|Direxion Daily S&P Biotech Bull 3x Shares Rises 8.25% in Regular Trading, Leveraged Biotech ETF Rebounds on Oversold Technical Repair

Market Focus
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Veeva Systems (VEEV) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Tilray (TLRY) and Viatris (VTRS)

TIPRANKS
·
Yesterday

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

GlobeNewswire
·
Yesterday

Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults

MT Newswires Live
·
Yesterday

Analysts’ Top Healthcare Picks: Biohaven Ltd. (BHVN), Clover Health Investments (CLOV)

TIPRANKS
·
Yesterday

Teva announces FDA approval for Weltruza

TIPRANKS
·
Yesterday

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

GlobeNewswire
·
Yesterday

National Healthcare Properties (NHP) Reaffirms Dividend, Is The Stock Still A Bargain?

Simply Wall St.
·
Yesterday

Health Care Roundup: Market Talk

Dow Jones
·
Yesterday

Humanwell Healthcare Unit Secures US FDA Nod for Angina Drug

MT Newswires Live
·
Yesterday

Sigma Healthcare Details ESG Strategy in 2026 Sustainability Report

TIPRANKS
·
Yesterday